Last Updated: November 9, 2026

CLINICAL TRIALS PROFILE FOR CLOLAR

« Back to Dashboard

All Clinical Trials for CLOLAR

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00067028 ↗	Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)	Completed	Genzyme, a Sanofi Company	Phase 2	2003-12-01	The goal is to compare the drug combinations clofarabine/idarubicin/ara-C, clofarabine/ara-C, and clofarabine/idarubicin in the treatment of patients with Acute Myeloid Leukemia, high-grade MDS, or myeloid blast phase of Chronic Myeloid Leukemia who have relapsed following their initial therapy.
NCT00067028 ↗	Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)	Completed	M.D. Anderson Cancer Center	Phase 2	2003-12-01	The goal is to compare the drug combinations clofarabine/idarubicin/ara-C, clofarabine/ara-C, and clofarabine/idarubicin in the treatment of patients with Acute Myeloid Leukemia, high-grade MDS, or myeloid blast phase of Chronic Myeloid Leukemia who have relapsed following their initial therapy.
NCT00081887 ↗	Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia	Terminated	Genzyme, a Sanofi Company	Phase 1	2004-05-01	Primary Objectives: 1. To determine the maximum tolerated dose (MTD) of clofarabine in Chronic Lymphocytic Leukemia (CLL). 2. To determine the toxicity profile of clofarabine in CLL. 3. To investigate the plasma clofarabine and cellular clofarabine triphosphate pharmacology profile of clofarabine in CLL.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for CLOLAR

Condition Name

Chart
Table

Condition Name for CLOLAR
Intervention	Trials
Leukemia	21
Acute Myeloid Leukemia	18
Myelodysplastic Syndrome	12
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for CLOLAR
Intervention	Trials
Leukemia	54
Leukemia, Myeloid, Acute	39
Leukemia, Myeloid	36
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for CLOLAR

Trials by Country

Map
Table

Trials by Country for CLOLAR
Location	Trials
United States	290
Canada	16
Australia	5
New Zealand	2
Israel	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for CLOLAR
Location	Trials
Texas	32
Washington	15
California	12
New York	11
Massachusetts	11
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for CLOLAR

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for CLOLAR
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	35
Phase 1/Phase 2	13
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for CLOLAR
Clinical Trial Phase	Trials
Completed	32
Terminated	14
Active, not recruiting	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CLOLAR

Sponsor Name

Chart
Table

Sponsor Name for CLOLAR
Sponsor	Trials
M.D. Anderson Cancer Center	25
National Cancer Institute (NCI)	24
Genzyme, a Sanofi Company	20
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for CLOLAR
Sponsor	Trials
Other	76
Industry	28
NIH	25
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.